Carlos Luri‐Rey

566 total citations · 1 hit paper
21 papers, 344 citations indexed

About

Carlos Luri‐Rey is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carlos Luri‐Rey has authored 21 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 18 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Carlos Luri‐Rey's work include CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (15 papers) and Immune Cell Function and Interaction (9 papers). Carlos Luri‐Rey is often cited by papers focused on CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (15 papers) and Immune Cell Function and Interaction (9 papers). Carlos Luri‐Rey collaborates with scholars based in Spain, United Kingdom and United States. Carlos Luri‐Rey's co-authors include Ignacio Melero, Álvaro Teijeira, Pedro Berraondo, Irene Olivera, Javier Glez‐Vaz, Assunta Cirella, Miguel F. Sanmamed, Elixabet Bolaños, Jun Wang and Lieping Chen and has published in prestigious journals such as Nature Medicine, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Carlos Luri‐Rey

20 papers receiving 335 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cross-priming in cancer immunology and immunotherapy

2025 33 citations Carlos Luri‐Rey, Álvaro Teijeira et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos Luri‐Rey Spain	11	218	203	93	48	32	21	344
Tiffany M. Marchell United States	3	189 0.9×	164 0.8×	89 1.0×	66 1.4×	21 0.7×	3	295
Mandy van Brakel Netherlands	10	179 0.8×	248 1.2×	88 0.9×	46 1.0×	50 1.6×	15	323
Irina Ganeeva Russia	9	132 0.6×	216 1.1×	130 1.4×	51 1.1×	56 1.8×	16	344
Esther Schoutrop Sweden	7	114 0.5×	170 0.8×	69 0.7×	45 0.9×	33 1.0×	8	274
Anne van Duffelen Netherlands	5	186 0.9×	177 0.9×	101 1.1×	55 1.1×	11 0.3×	6	346
Anuradha Khilnani United States	7	247 1.1×	152 0.7×	94 1.0×	27 0.6×	26 0.8×	9	328
Don G. Lee South Korea	11	251 1.2×	191 0.9×	69 0.7×	25 0.5×	25 0.8×	13	355
Paul Shafer United States	5	153 0.7×	200 1.0×	85 0.9×	23 0.5×	40 1.3×	8	290
Donghua Shi China	5	158 0.7×	254 1.3×	68 0.7×	55 1.1×	42 1.3×	7	353
Lieke L. van der Woude Netherlands	6	187 0.9×	212 1.0×	77 0.8×	38 0.8×	21 0.7×	10	306

Countries citing papers authored by Carlos Luri‐Rey

Since Specialization

Citations

This map shows the geographic impact of Carlos Luri‐Rey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Luri‐Rey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Luri‐Rey more than expected).

Fields of papers citing papers by Carlos Luri‐Rey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Luri‐Rey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Luri‐Rey. The network helps show where Carlos Luri‐Rey may publish in the future.

Co-authorship network of co-authors of Carlos Luri‐Rey

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Luri‐Rey. A scholar is included among the top collaborators of Carlos Luri‐Rey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Luri‐Rey. Carlos Luri‐Rey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luri‐Rey, Carlos, et al.. (2025). Antigen-presenting mast cells are new players in breast cancer immunotherapy. Nature Medicine. 31(7). 2123–2125.

Berraondo, Pedro, Fernando Aranda, Iñaki Eguren‐Santamaría, et al.. (2025). Immunocytokines and cytokine neutralization for cancer immunotherapy. Trends in cancer. 11(8). 790–805. 3 indexed citations

Luri‐Rey, Carlos, Álvaro Teijeira, Stefanie K. Wculek, et al.. (2025). Cross-priming in cancer immunology and immunotherapy. Nature reviews. Cancer. 25(4). 249–273. 33 indexed citations breakdown →

Fernández, Leticia, Carlos E. de Andrea, Álvaro Teijeira, et al.. (2025). 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models. Journal for ImmunoTherapy of Cancer. 13(2). e009852–e009852. 4 indexed citations

Olivera, Irene, et al.. (2024). Regional and intratumoral adoptive T-cell therapy. Immuno-Oncology Technology. 24. 100715–100715. 4 indexed citations

Olivera, Irene, Elixabet Bolaños, Sandra Hervás‐Stubbs, et al.. (2023). mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Reports Medicine. 4(3). 100978–100978. 32 indexed citations

Luri‐Rey, Carlos, et al.. (2023). Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming. Immunological Reviews. 321(1). 143–151. 10 indexed citations

Cirella, Assunta, Elixabet Bolaños, Carlos Luri‐Rey, et al.. (2023). Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists. Molecular Therapy — Nucleic Acids. 33. 668–682. 6 indexed citations

Glez‐Vaz, Javier, Arantza Azpilikueta, María C. Ochoa, et al.. (2023). CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects. Science Advances. 9(33). eadf6692–eadf6692. 6 indexed citations

10.

Olivera, Irene, Carlos Luri‐Rey, Álvaro Teijeira, et al.. (2023). Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy. Clinical Cancer Research. 29(23). 4711–4727. 2 indexed citations

11.

Ochoa, María C., Carlos E. de Andrea, Saray Garasa, et al.. (2023). Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Reports Medicine. 4(4). 101009–101009. 16 indexed citations

12.

Álvarez, Maite, Carmen Molina, Saray Garasa, et al.. (2023). Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic. OncoImmunology. 12(1). 2197370–2197370. 10 indexed citations

13.

Melero, Ignacio, María C. Ochoa, Carmen Molina, et al.. (2023). Intratumoral co‐injection of NK cells and NKG2A ‐neutralizing monoclonal antibodies. EMBO Molecular Medicine. 15(11). e17804–e17804. 13 indexed citations

14.

Melero, Ignacio, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.. (2022). CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery. 13(3). 552–569. 51 indexed citations

15.

Glez‐Vaz, Javier, Arantza Azpilikueta, Irene Olivera, et al.. (2022). Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Journal for ImmunoTherapy of Cancer. 10(3). e003532–e003532. 13 indexed citations

16.

Teijeira, Álvaro, Saray Garasa, Carlos Luri‐Rey, et al.. (2022). Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy. Cancer Research. 82(23). 4373–4385. 22 indexed citations

17.

Cirella, Assunta, Carlos Luri‐Rey, Álvaro Teijeira, et al.. (2022). Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacology & Therapeutics. 239. 108189–108189. 74 indexed citations

18.

Glez‐Vaz, Javier, Arantza Azpilikueta, Irene Olivera, et al.. (2022). Abstract 628: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Cancer Research. 82(12_Supplement). 628–628. 1 indexed citations

19.

Olivera, Irene, Elixabet Bolaños, Sandra Hervás‐Stubbs, et al.. (2022). 267 mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Regular and Young Investigator Award Abstracts. A282–A282. 1 indexed citations

20.

Teijeira, Álvaro, Itziar Miguéliz, Saray Garasa, et al.. (2022). Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics. 12(3). 1373–1387. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact